FA
PHAT icon

FCG Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

FCG Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$598K Hold
16,300
– – 0.14% 83
2020
Q2 		$536K Hold
16,300
– – 0.14% 73
2020
Q1 		$421K Buy
+16,300
New +$545K 0.12% 84

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCG Advisors's PHAT Position: Q3 2020 in Review

FCG Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q3 2020 at 16,300 shares worth $598K. The position accounts for 0.14% of the portfolio, ranked #83.

FCG Advisors first reported a position in PHAT in Q1 2020 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold PHAT as of Q3 2020.

  • FCG Advisors held 16,300 shares of Phathom Pharmaceuticals worth $598K as of Q3 2020.
  • FCG Advisors left its Phathom Pharmaceuticals share count unchanged in Q3 2020.
  • Phathom Pharmaceuticals made up 0.14% of FCG Advisors's portfolio in Q3 2020, its #83 holding.
  • FCG Advisors first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 3 quarters since.
  • 58 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.